Botulinum toxin type A
- Generic Name
- Botulinum toxin type A
- Brand Names
- Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- 0A6JH35GMQ
- Background
In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other condit...
- Indication
Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.
...
- Associated Conditions
- Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
- Associated Therapies
- -
A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
- First Posted Date
- 2011-03-03
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 335
- Registration Number
- NCT01308060
Determination of the Optimum Delivery Route for Botulinum Toxin A in Patients With Epiphora
- First Posted Date
- 2011-01-25
- Last Posted Date
- 2012-09-12
- Lead Sponsor
- Merbs, Shannath, M.D., Ph.D.
- Target Recruit Count
- 26
- Registration Number
- NCT01282541
- Locations
- 🇺🇸
Wilmer Eye Institute, Baltimore, Maryland, United States
Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy
- Conditions
- Interventions
- First Posted Date
- 2011-01-13
- Last Posted Date
- 2011-01-19
- Lead Sponsor
- Universita di Verona
- Target Recruit Count
- 18
- Registration Number
- NCT01276015
Botox and Suction-Curettage for Treatment of Excessive Underarm Sweating (Axillary Hyperhidrosis)
- Conditions
- Interventions
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2021-12-06
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 20
- Registration Number
- NCT01274611
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Department of Dermatology, Chicago, Illinois, United States
Use of Botox in the Management of Thyroid Related Upper Eyelid Retraction
- Conditions
- Interventions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- University of Toronto
- Registration Number
- NCT01272414
- Locations
- 🇨🇦
Mount Sinai Hospital, Toronto, Ontario, Canada
Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2014-12-16
- Lead Sponsor
- AboutSkin Dermatology and DermSurgery, PC
- Target Recruit Count
- 156
- Registration Number
- NCT01269801
- Locations
- 🇨🇦
Niagara Falls Dermantology and Skin Care Center, Niagara Falls, Ontario, Canada
🇨🇦University of Toronto, Toronto, Ontario, Canada
🇺🇸About Skin Dermatology, Englewood, Colorado, United States
BTX-A Treatment for Palmar Hyperhidrosis
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 2
- Registration Number
- NCT01262339
- Locations
- 🇺🇸
University of Wisconsin-Madison, Madison, Wisconsin, United States
Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm
- First Posted Date
- 2010-12-14
- Last Posted Date
- 2012-04-25
- Lead Sponsor
- Medy-Tox
- Target Recruit Count
- 110
- Registration Number
- NCT01259557
- Locations
- 🇰🇷
Seoul St.Mary Hospital, Seoul, Korea, Republic of
🇰🇷Sevrance Hospital, Seoul, Korea, Republic of
🇰🇷Chung-Ang Univesity Yongsan Hospital, Seoul, Korea, Republic of
The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Medy-Tox
- Target Recruit Count
- 212
- Registration Number
- NCT01256021
- Locations
- 🇰🇷
Seoul National Universtiy Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
Botulinum Toxin in Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2010-12-01
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Hospital Ambroise Paré Paris
- Target Recruit Count
- 66
- Registration Number
- NCT01251211
- Locations
- 🇧🇷
Divisão de Clínica Neurológica do Hospital das Clínicas da FMUSP, Sao Paulo, Brazil
🇫🇷Hôpital Ambroise Paré, APHP, Boulogne-Billancourt, France
🇫🇷Hôpital Dupuytren, Limoges, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.